Revenue
0 USD
2026 Q3 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Annual consolidated revenue for 2025: about USD 0, using the latest filing vintage with reviewed corrections applied. Corrected values apply reviewed corrections and remain separate from issuer reports. The previous period, 2023, was about USD 300K.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
Window: transactions dated on or after 2025-11-19.
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
These figures cover less than a full year. They are not annualized and are excluded from full-year trends and comparisons.
| Measure | Period | Value |
|---|---|---|
| Net income | 2024-08-01 – 2024-12-31 | -53763000 USD Source Dispute |
| Capital expenditure | 2024-01-01 – 2024-07-30 | 368000 USD Source Dispute |
| Cost of revenue | 2024-01-01 – 2024-07-30 | 1381000 USD Source Dispute |
| Gross profit | 2024-01-01 – 2024-07-30 | -1048000 USD Source Dispute |
| Net income | 2024-01-01 – 2024-07-30 | -21300000 USD Source Dispute |
| Operating cash flow | 2024-01-01 – 2024-07-30 | -15990000 USD Source Dispute |
| Operating income | 2024-01-01 – 2024-07-30 | -21680000 USD Source Dispute |
| Research and development | 2024-01-01 – 2024-07-30 | 7585000 USD Source Dispute |
| Revenue | 2024-01-01 – 2024-07-30 | 333000 USD Source Dispute |
| Selling, general and administrative | 2024-01-01 – 2024-07-30 | 13047000 USD Source Dispute |
0 USD
2026 Q3 · USD
-4.6 million USD
2026 Q3 · USD
-4.6 million USD
2026 Q3 · USD
3100000 USD
2010000 USD
889644 shares
-94.22% · -14.5 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
0 USD
2025-10-01 – 2026-09-30
818 thousand USD
2025-10-01 – 2026-09-30
Latest filing vintage with reviewed corrections applied; these values remain separate from issuer-reported figures. Annual charts exclude incomplete years.
Latest filing recorded: 2026-11-16.
Financial data available through: 2025-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
No unambiguous prior-year comparison is available for the latest reporting period.
Comparable inputs unavailable for: Revenue, Net income, Operating cash flow, Capital expenditure.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | 300000 | 28242000 Derived | -27942000 | 8658000 Derived | -36600000 | -26033000 Derived | Source
|
| 2025 2025-01-01 – 2025-12-31 | 0 | 21890000 Derived | -21890000 | 3210000 Derived | -25100000 | -19388000 Derived | Source
|
Amounts are exact, in USD.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Revenue | 300000 |
|
| 2025 | Revenue | 0 |
|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Year over year | No prior comparable period |
|
| 2025 | Year over year | No prior comparable period |
|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Operating margin | -9,314% |
|
| 2025 | Operating margin | Not reported |
|
| 2023 | Net margin | -12,200% |
|
| 2025 | Net margin | Not reported |
|
| 2023 | Free cash flow margin | -8,677.7% |
|
| 2025 | Free cash flow margin | Not reported |
|
Cash generated by the company’s normal business operations.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Operating cash flow | -25700000 |
|
| 2025 | Operating cash flow | -19014000 |
|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Free cash flow | -26033000 |
|
| 2025 | Free cash flow | -19388000 |
|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Liabilities / assets | 694.2% |
|
| 2025 | Liabilities / assets | 71.3% |
|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Current assets / current liabilities | 0.11× |
|
| 2025 | Current assets / current liabilities | 2.44× |
|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 36.6 million Exact valueExact value: -36600000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 25.7 million Exact valueExact value: -25700000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 333,000 Exact valueExact value: 333000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 26.03 million Calculation and evidence-25700000 − 333000 USD Exact free cash flow: -26033000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 25.1 million Exact valueExact value: -25100000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 19.01 million Exact valueExact value: -19014000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 374,000 Exact valueExact value: 374000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 19.39 million Calculation and evidence-19014000 − 374000 USD Exact free cash flow: -19388000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
21 filings · 977 latest values · 972 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0002006986, 2006986, ADGM, edgar:2006986
Also known as ADAGIO MEDICAL HOLDINGS, INC., ADAGIO MEDICAL HOLDINGS, INC., Adagio Medical Holdings, Inc., Adagio Medical Holdings, Inc., Aja Holdco, Inc.